Bioavailability of a novel sustained‐release pellet formulation of 5‐flucytosine in healthy‐fed participants for use in patients with cryptococcal meningitisNabila Ibnou Zekri Lassout, Isabela Ribeiro, Anouk Neven et al.|Clinical and Translational Science|2024Cited by 2
PA-298 Predicting disease effect on the pharmacokinetics (PK) of sustained and immediate release formulations by applying physiologically based pharmacokinetic (PBPK) modellingJohanna Eriksson, Marylore Chenel, Eric B. Sjogren et al.|Unknown|2023Cited by 0